Functional genomic landscape of acute myeloid leukaemia
Jeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, Beth Wilmot, Stephen E Kurtz, Samantha L Savage, Nicola Long, Anna Reister Schultz, Elie Traer, Melissa Abel, Anupriya Agarwal, Aurora Blucher, Uma Borate, Jade Bryant, Russell Burke, Amy Carlos, Richie Carpenter, Joseph Carroll, Bill H Chang, Cody Coblentz, Amanda d'Almeida, Rachel Cook, Alexey Danilov, Kim-Hien T Dao, Michie Degnin, Deirdre Devine, James Dibb, David K Edwards 5th, Christopher A Eide, Isabel English, Jason Glover, Rachel Henson, Hibery Ho, Abdusebur Jemal, Kara Johnson, Ryan Johnson, Brian Junio, Andy Kaempf, Jessica Leonard, Chenwei Lin, Selina Qiuying Liu, Pierrette Lo, Marc M Loriaux, Samuel Luty, Tara Macey, Jason MacManiman, Jacqueline Martinez, Motomi Mori, Dylan Nelson, Ceilidh Nichols, Jill Peters, Justin Ramsdill, Angela Rofelty, Robert Schuff, Robert Searles, Erik Segerdell, Rebecca L Smith, Stephen E Spurgeon, Tyler Sweeney, Aashis Thapa, Corinne Visser, Jake Wagner, Kevin Watanabe-Smith, Kristen Werth, Joelle Wolf, Libbey White, Amy Yates, Haijiao Zhang, Christopher R Cogle, Robert H Collins, Denise C Connolly, Michael W Deininger, Leylah Drusbosky, Christopher S Hourigan, Craig T Jordan, Patricia Kropf, Tara L Lin, Micaela E Martinez, Bruno C Medeiros, Rachel R Pallapati, Daniel A Pollyea, Ronan T Swords, Justin M Watts, Scott J Weir, David L Wiest, Ryan M Winters, Shannon K McWeeney, Brian J Druker, Jeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, Beth Wilmot, Stephen E Kurtz, Samantha L Savage, Nicola Long, Anna Reister Schultz, Elie Traer, Melissa Abel, Anupriya Agarwal, Aurora Blucher, Uma Borate, Jade Bryant, Russell Burke, Amy Carlos, Richie Carpenter, Joseph Carroll, Bill H Chang, Cody Coblentz, Amanda d'Almeida, Rachel Cook, Alexey Danilov, Kim-Hien T Dao, Michie Degnin, Deirdre Devine, James Dibb, David K Edwards 5th, Christopher A Eide, Isabel English, Jason Glover, Rachel Henson, Hibery Ho, Abdusebur Jemal, Kara Johnson, Ryan Johnson, Brian Junio, Andy Kaempf, Jessica Leonard, Chenwei Lin, Selina Qiuying Liu, Pierrette Lo, Marc M Loriaux, Samuel Luty, Tara Macey, Jason MacManiman, Jacqueline Martinez, Motomi Mori, Dylan Nelson, Ceilidh Nichols, Jill Peters, Justin Ramsdill, Angela Rofelty, Robert Schuff, Robert Searles, Erik Segerdell, Rebecca L Smith, Stephen E Spurgeon, Tyler Sweeney, Aashis Thapa, Corinne Visser, Jake Wagner, Kevin Watanabe-Smith, Kristen Werth, Joelle Wolf, Libbey White, Amy Yates, Haijiao Zhang, Christopher R Cogle, Robert H Collins, Denise C Connolly, Michael W Deininger, Leylah Drusbosky, Christopher S Hourigan, Craig T Jordan, Patricia Kropf, Tara L Lin, Micaela E Martinez, Bruno C Medeiros, Rachel R Pallapati, Daniel A Pollyea, Ronan T Swords, Justin M Watts, Scott J Weir, David L Wiest, Ryan M Winters, Shannon K McWeeney, Brian J Druker
Abstract
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Here we report initial findings from the Beat AML programme on a cohort of 672 tumour specimens collected from 562 patients. We assessed these specimens using whole-exome sequencing, RNA sequencing and analyses of ex vivo drug sensitivity. Our data reveal mutational events that have not previously been detected in AML. We show that the response to drugs is associated with mutational status, including instances of drug sensitivity that are specific to combinatorial mutational events. Integration with RNA sequencing also revealed gene expression signatures, which predict a role for specific gene networks in the drug response. Collectively, we have generated a dataset-accessible through the Beat AML data viewer (Vizome)-that can be leveraged to address clinical, genomic, transcriptomic and functional analyses of the biology of AML.
Figures
References
- Jemal A, Siegel R, Xu J & Ward E Cancer statistics, 2010. CA: a cancer journal for clinicians 60, 277–300, (2010).
- National Cancer Institute: Surveillance, Epidemiology, and End Results Program, <> (2018).
- Papaemmanuil E et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374, 2209–2221, (2016).
- Arber DA et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405, (2016).
- Dohner H et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424–447, (2017).
- TCGA. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368, 2059–2074, (2013).
- Byrd JC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325–4336, (2002).
- Patel JP et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366, 1079–1089, (2012).
- Haferlach T et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247, (2014).
- Lundberg P et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123, 2220–2228, (2014).
- Deininger MWN, Tyner JW & Solary E Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat Rev Cancer 17, 425–440, (2017).
- Busque L et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 44, 1179–1181, (2012).
- Genovese G et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371, 2477–2487, (2014).
- Jaiswal S et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371, 2488–2498, (2014).
- Xie M et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20, 1472–1478, (2014).
- Huang ME et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567–572, (1988).
- Shen ZX et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354–3360, (1997).
- Nakao M et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10, 1911–1918, (1996).
- Tse KF, Mukherjee G & Small D Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14, 1766–1776, (2000).
- Yamamoto Y et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97, 2434–2439, (2001).
- Yokota S et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11, 1605–1609, (1997).
- Knapper S et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108, 3262–3270, (2006).
- O’Farrell AM et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9, 5465–5476, (2003).
- Smith BD et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669–3676, (2004).
- DeAngelo DJ et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108, 3674–3681, (2006).
- Stone RM et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377, 454–464, (2017).
- Mardis ER et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361, 1058–1066, (2009).
- Wang F et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622–626, (2013).
- Rohle D et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626–630, (2013).
- Fiskus W et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114, 2733–2743, (2009).
- Schenk T et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18, 605–611, (2012).
- Daigle SR et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53–65, (2011).
- Itzykson R et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25, 1147–1152, (2011).
- Welch JS et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 375, 2023–2036, (2016).
- Konopleva M et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov 6, 1106–1117, (2016).
- DiNardo CD et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol, (2018).
- Tyner JW et al. Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Res 73, 285–296, (2013).
- Benjamini Y & Hochberg Y Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological) 57, 289–300, (1995).
- Puissant A et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell 25, 226–242, (2014).
- Canisius S, Martens JWM & Wessels LFA A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome biology 17, 261, (2016).
- Li H & Durbin R Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760, (2009).
- McKenna A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297–1303, (2010).
- Huntley MA et al. ReportingTools: an automated result processing and presentation toolkit for high-throughput genomic analyses. Bioinformatics 29, 3220–3221, (2013).
- Buffalo V qrqc: Quick Read Quality Control. R package version 1.22.0, . (2012).
- Cibulskis K et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31, 213–219, (2013).
- Koboldt DC et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22, 568–576, (2012).
- McLaren W et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069–2070, (2010).
- Kandoth, C. .
- varscan: Variant calling and somatic mutation/CNV detection for next-generation sequencing data (2018).
- vcf2maf: Convert a VCF into a MAF, where each variant is annotated to only one of all possible gene isoforms (Memorial Sloan Kettering, 2018).
- Zhao H et al. CrossMap: a versatile tool for coordinate conversion between genome assemblies. Bioinformatics 30, 1006–1007, (2014).
- Lek M et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291, (2016).
- Ye K, Schulz MH, Long Q, Apweiler R & Ning Z Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865–2871, (2009).
- Costello M et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Research 41, e67, (2013).
- Kottaridis PD et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98, 1752–1759, (2001).
- Dohner K et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106, 3740–3746, (2005).
- Falini B, Nicoletti I, Martelli MF & Mecucci C Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 109, 874–885, (2007).
- Huang Q et al. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol 142, 489–492, (2008).
- Wouters BJ et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113, 3088–3091, (2009).
- Liao Y, Smyth GK & Shi W The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res 41, e108, (2013).
- Liao Y, Smyth GK & Shi W featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930, (2014).
- Langfelder P & Horvath S WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics 9, 559, (2008).
- Hansen KD, Irizarry RA & Wu Z Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics 13, 204–216, (2012).
- Kim D & Salzberg SL TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome biology 12, R72, (2011).
- Langfelder P & Horvath S Fast R Functions for Robust Correlations and Hierarchical Clustering. Journal of Statistical Software 46, (2012).
- Langfelder P, Luo R, Oldham MC & Horvath S Is My Network Module Preserved and Reproducible? PLoS computational biology 7, e1001057, (2011).
- Parsana P et al. Addressing confounding artifacts in reconstruction of gene co-expression networks. bioRxiv, 202903, (2017).
- Zheng X et al. A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics 28, 3326–3328, (2012).
- International HapMap C The International HapMap Project. Nature 426, 789–796, (2003).
- Zheng X & Weir BS Eigenanalysis of SNP data with an identity by descent interpretation. Theoretical Population Biology 107, 65–76, (2016).
- Robinson MD & Oshlack A A scaling normalization method for differential expression analysis of RNA-seq data. Genome biology 11, R25, (2010).
- Slovak ML, Theisen A & Shaffer LG in The Principles of Clinical Cytogenetics (eds Gersen Steven L. & Keagle Martha B.) 23–49 (Springer; New York, 2013).
- Kurtz SE et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A 114, E7554–E7563, (2017).
- Davis MI et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29, 1046–1051, (2011).
- Blucher AS, Choonoo G, Kulesz-Martin M, Wu G & McWeeney SK Evidence-Based Precision Oncology with the Cancer Targetome. Trends in pharmacological sciences 38, 1085–1099, (2017).
- Gu Z, Eils R & Schlesner M Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849, (2016).
- Ritchie ME et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research 43, e47–e47, (2015).
- Leek JT & Storey JD Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis. PLOS Genetics 3, e161, (2007).
- Law CW, Chen Y, Shi W & Smyth GK voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome biology 15, R29, (2014).
- Parker HS, Bravo HC & Leek JT Removing batch effects for prediction problems with frozen surrogate variable analysis. PeerJ 2, e561, (2014).
- Fraley C & Raftery AE Enhanced Model-Based Clustering, Density Estimation, and Discriminant Analysis Software: MCLUST. Journal of Classification 20, 263–286, (2003).
- Pison G, Struyf A & Rousseeuw PJ Displaying a clustering with CLUSPLOT. Computational Statistics & Data Analysis 30, 381–392, (1999).
- Package corrplot is for visualizing a correlation matrix (2018).
- Tibshirani R Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistical Society. Series B (Methodological) 58, 267–288, (1996).
- Friedman J, Hastie T & Tibshirani R Regularization Paths for Generalized Linear Models via Coordinate Descent. Journal of Statistical Software 33, (2010).
- Iorio F et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 166, 740–754, (2016).
Source: PubMed